36 is the new 18: Functional high‐risk multiple myeloma in the modern era
In this issue of Cancer , a threshold of 36 months (rather than 18 months) is established as the optimal threshold for the identification of functional high‐risk multiple myeloma. Early use of T‐cell–redirection therapies may improve outcomes for these patients.
Authors
- Swetha Reddi
- Rahul Kumar Banerjee (ORCID: https://orcid.org/0000-0003-3781-5441)
Institutions
- University of Washington (US)
- Fred Hutch Cancer Center (US)
Publication Details
- Journal
- Cancer
- Published
- 2026-07-24
- DOI
- https://doi.org/10.1002/cncr.70548
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00